Relative Bioavailability of Apixaban Solution or Crushed Tablet Formulations Administered by Mouth or Nasogastric Tube in Healthy Subjects

Clinical Therapeutics

Volumn 37, Issue 8, 2015, Pages 1703-1712

  Song, Yan ^a   Wang, Xiaoli ^a   Perlstein, Itay ^a   Wang, Jessie ^a   Badawy, Sherif ^a   Frost, Charles ^a   Lacreta, Frank ^a  

^a BRISTOL MYERS SQUIBB   (United States)

Author keywords

apixaban; bioavailability; crushed tablet; nasogastric tube

Indexed keywords

APIXABAN; BLOOD CLOTTING FACTOR 10A INHIBITOR; PYRAZOLE DERIVATIVE; PYRIDONE DERIVATIVE;

ADULT; AREA UNDER THE CURVE; ARTICLE; ARTIFICIAL MILK; BIOEQUIVALENCE; CONTROLLED STUDY; CROSSOVER PROCEDURE; DRUG BIOAVAILABILITY; DRUG INDUCED HEADACHE; DRUG TOLERABILITY; DRUG WITHDRAWAL; HUMAN; NASOGASTRIC TUBE; OPEN STUDY; PARONYCHIA; RANDOMIZED CONTROLLED TRIAL; SINGLE DRUG DOSE; STOMACH CARCINOMA; TABLET FORMULATION; TIME TO MAXIMUM PLASMA CONCENTRATION; TOOTH PAIN; ADOLESCENT; ATRIAL FIBRILLATION; BIOAVAILABILITY; BLOOD; CHEMISTRY; DIGESTIVE TRACT INTUBATION; FEMALE; MALE; MEDICINAL CHEMISTRY; MIDDLE AGED; ORAL DRUG ADMINISTRATION; TREATMENT OUTCOME; YOUNG ADULT;

ADMINISTRATION, ORAL; ADOLESCENT; ADULT; AREA UNDER CURVE; ATRIAL FIBRILLATION; BIOLOGICAL AVAILABILITY; CHEMISTRY, PHARMACEUTICAL; CROSS-OVER STUDIES; FACTOR XA INHIBITORS; FEMALE; HUMANS; INTUBATION, GASTROINTESTINAL; MALE; MIDDLE AGED; PYRAZOLES; PYRIDONES; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84940567377     PISSN: 01492918     EISSN: 1879114X     Source Type: Journal    
DOI: 10.1016/j.clinthera.2015.05.497     Document Type: Article

References (31)

1. S.J. Connolly, J. Eikelboom, C. Joyner, and et al. Apixaban in patients with atrial fibrillation N Engl J Med 364 2011 806 817
2. C.B. Granger, J.H. Alexander, J.J. McMurray, and et al. Apixaban versus warfarin in patients with atrial fibrillation N Engl J Med 365 2011 981 992
3. M.R. Lassen, G.E. Raskob, A. Gallus, and et al. Apixaban versus enoxaparin for thromboprophylaxis after knee replacement (ADVANCE-2): a randomised double-blind trial Lancet 375 2010 807 815
4. M.R. Lassen, A. Gallus, G.E. Raskob, and et al. Apixaban versus enoxaparin for thromboprophylaxis after hip replacement N Engl J Med 363 2010 2487 2498
5. G. Agnelli, H.R. Buller, A. Cohen, and et al. Apixaban for extended treatment of venous thromboembolism N Engl J Med 368 2013 699 708
6. G. Agnelli, H.R. Buller, A. Cohen, and et al. Oral apixaban for the treatment of acute venous thromboembolism N Engl J Med 369 2013 799 808
7. Bristol-Myers Squibb. Eliquis (apixaban tablets) [prescribing information]. http://packageinserts.bms.com/pi/pi-eliquis.pdf. Accessed February 4, 2013.
8. L.X. Yu, G.L. Amidon, J.E. Polli, and et al. Biopharmaceutics classification system: the scientific basis for biowaiver extensions Pharm Res 19 2002 921 925
9. C. Frost, X. Wang, S. Nepal, and et al. Assessment of the sites of gastrointestinal absorption of apixaban in healthy subjects Clin Pharmacol Drug Dev 2 suppl 1 2013 19 Abstract 1703161
10. C. Frost, S. Nepal, J. Wang, and et al. Safety, pharmacokinetics and pharmacodynamics of multiple oral doses of apixaban, a factor Xa inhibitor, in healthy subjects Br J Clin Pharmacol 76 2013 776 786
11. N. Raghavan, C.E. Frost, Z. Yu, and et al. Apixaban metabolism and pharmacokinetics after oral administration to humans Drug Metab Dispos 37 2009 74 81
12. D. Zhang, K. He, N. Raghavan, and et al. Comparative metabolism of 14C-labeled apixaban in mice, rats, rabbits, dogs, and humans Drug Metab Dispos 37 2009 1738 1748
13. S. Lindgren, and L. Jazon Prevalence of swallowing complaints and clinical findings among 50-70 year old men and women in an urban population Dysphagia 6 1991 187 192
14. N.J. Talley, A.L. Weaver, A.R. Zinsmeister, and et al. Onset and disappearance of gastrointestinal symptoms and functional gastrointestinal disorders Am J Epidemiol 136 1992 165 177
15. G. Kjellen, and L. Tibbling Manometric oesophageal function, acid perfusion test and symptomatology in a 55-year-old general population Clin Physiol 1 1981 405 415
16. B.R. Bloem, A.M. Lagaay, W. van Beek, and et al. Prevalence of subjective dysphagia in community residents aged over 87 Br Med J 300 1990 721 722
17. K. Kawashima, Y. Motohashi, and I. Fijishima Prevalence of dysphagia among community-dwelling elderly individuals as estimated using a questionnaire for dysphagia screening Dysphagia 19 2004 266 271
18. G.D. Eslick, and N.J. Talley Dysphagia: epidemiology, risk factors and impact on quality of life-a population-based study Aliment Pharmacol Ther 27 2008 971 979
19. I. Strachan, and M. Greener Medication-related swallowing difficulties may be more common than we realise Pharmacy Practice 15 2005 411 414
20. E.S. Dodds Ashley, A.K. Zaas, A.F. Fang, and et al. Comparative pharmacokinetics of voriconazole administered orally as either crushed or whole tablets Antimicrob Agents Chemother 51 2007 877 880
21. R. White, and V. Bradnam Handbook of Drug Administration via Enteral Feeding Tubes 2007 Pharmaceutical Press London
22. N.T. Williams Medication administration through enteral feeding tubes Am J Health Syst Pharm 65 2008 2347 2357
23. J. Pursley, J.X. Shen, A. Schuster, and et al. LC-MS/MS Determination of apixaban (BMS-562247) and its major metabolite in human plasma - an application of polarity switching and monolithic HPLC column Future Science 6 2014 2071 2082
24. C. Frost, S. Nepal, Y. Barrett, and et al. Effects of age and gender on the single-dose pharmacokinetics (PK) and pharmacodynamics (PD) of apixaban J Thromb Haemost 7 2009 PP-MO-407
25. C. Frost, J. Wang, S. Nepal, and et al. Apixaban, an oral, direct factor Xa inhibitor: single-dose safety, pharmacokinetics, pharmacodynamics and food effect in healthy subjects Br J Clin Pharmacol 75 2013 476 487
26. A.L. Clark-Schmidt, W.R. Garnett, D.R. Lowe, and H.T. Karnes Loss of carbamazepine suspension through nasogastric feeding tubes Am J Hosp Pharm 47 1990 2034 2037
27. D. Adams Administration of drugs through a jejunostomy tube Br J Intensiv Care 4 1994 10 17
28. D. Fleisher, C. Li, Y. Zhou, and et al. Drug, meal and formulation interactions influencing drug absorption after oral administration: clinical implications Clin Pharmacokinet 36 1999 233 254
29. M.U. Zafar, M.E. Farkouh, V. Fuster, and J.H. Chesebro Crushed clopidogrel administered via nasogastric tube has faster and greater absorption than oral whole tablets J Interv Cardiol 22 2009 385 389
30. Boehringer Ingelheim. Pradaxa (dabigatran etexilate) capsules [prescribing information]. http://www.accessdata.fda.gov/drugsatfda-docs/label/2013/022512s017lbl.pdf. Accessed October 13, 2014.
31. L.E. Penrod, J.B. Allen, and L.R. Cabacungan Warfarin resistance and enteral feedings: 2 case reports and a supporting in vitro study Arch Phys Med Rehabil 82 2001 1270 1273